SAGA Diagnostics is a newly established modern clinical research laboratory, with a novel and unique biomarker method for detecting recurrence of cancer. The technology is based on blood sample analysis to detect circulating tumour DNA (ctDNA). SAGA Diagnostics are experts in the field of ctDNA analysis. The company develops proprietary patented molecular genetic tests with unsurpassed specificity, and between 10 and 100 times more sensitive than standard methods. SAGA Diagnostics’ unique method makes it possible to detect recurring cancers much earlier than the conventional methods in clinical use today would allow.
WntResearch has entered into an agreement with SAGA Diagnostics regarding the KROMA™ technology for the detection and measurement of circulating tumour DNA (ctDNA) in the blood. High levels of ctDNA have been shown to be strongly linked to early relapse in cancer disease. By measuring ctDNA in blood samples, the cancer can be monitored continously during treatment; recurrence can be observed as early as 36 months before metastasis can be detected with current imaging technologies. Studies have shown that the KROMA technology is more robust and has higher precision compared to other assay methods for determining ctDNA. With ctDNA, the treatment success in clinical studies have been found significantly earlier than with imaging technologies such as computer tomography (CT scan) and magnetic resonance imaging (MR / MRI).